FTSE 100 gains after Bank of England hikes rates, US Stocks surge

The FTSE 100 finished Thursday higher after the Bank of England raised rates by 50bps to 4% and signalled a milder UK recession than first thought.

The Bank of England also amended their inflation forecast to just 4% by the end of the year.

“The Bank is now projecting that inflation will fall to 4% by the end of the year, which will be music to the ears of the PM, who has promised a halving in the inflation rate – though the Bank might legitimately be a little peeved the government is trying to claim credit for their efforts,” said Laith Khalaf, head of investment analysis at AJ Bell.

“Inflation is now forecast to fall to 0.4% in 2026, which begs the question why the Bank is continuing to raise interest rates.”

The Bank of England was joined by the ECB in hiking 50bps on Thursday. However, the biggest story in town was the US Federal Reserve’s more conservative 25bps rate hike last night.

The slowing pace of US rate hikes and generally dovish comments from the Federal Reserve Chair proved ample to support global risk assets and the Bank of England’s instalment helped boost momentum in equity markets.

The Federal Reserve said that although rates would continue to rise in 2023, it would be at a slower pace than 2022. Bond yields fell across major economies as a result – this is welcome news for equity investors.

The Fed Chair really fired up equity bulls when as he said the “disinflationary process has started”, opening the doors for easier monetary policy in the future.

The FTSE 100 touched 7,840 in mid afternoon trade before falling back to 7,820 at the close. US stocks stormed ahead with the S&P 500 jumping 1.5% and the NASDAQ surging 3%.

Shell record profits

Shell provided substantial support for the index on Thursday following the confirmation of record profits in 2022 due to higher energy prices. Shell earnings hit $40bn in 2022, although some areas of the business started to slow down in the 4th quarter.

Following a sharp rally in Facebook-owner Meta last night and the NASDAQ today, Ocado once more demonstrated its tech stock attributes as it jumped 11% in a broad global tech rally.

The tech-heavy Scottish Mortgage Trust was also among the top risers, gaining 6%. The trust’s largest holdings include Tesla, Tencent, and Amazon. Moderna is the trust’s top holding, accounting for 10% of the portfolio.

JD Sports also gained 11% meaning the retailer has nearly doubled from lows at the end of 2022. The prospect of lower inflation could mean increased discretionary spending on JD’s £160 trainers.

AIM movers: Immotion cash return and ex-dividends

2

Immotion (LON: IMMO) is selling its location-based entertainment business for $25.1m, having raised £100,000 from disposing of Uvisan. Shareholders are likely to receive 3p a share out of the sale proceeds with £6.5m retained for the remaining business after buying back shares from management leaving with the location-based entertainment business. Immotion will concentrate on the home-based entertainment business Let’s Explore Media. This will be expanded via acquisitions. The share price jumped 53.4% to 3.375p. Immotion joined AIM in July 2018 at a placing price of 10p a share.

Digital advertising services provider Dianomi (LON: DNM) says revenues were £35.8m in 2022 and EBITDA was £1.5m. There is a strong pipeline of potential new business this year and management indicates that second quarter advertising budgets are expected to improve. Even so, the growth rate of digital advertising has slowed. Dianomi is cautious about prospects and reducing costs, but after a long period of decline the share price has reacted positively, rising 25.9% to 85p.

AI-based cyber security services provider Smarttech247 (LON: S247) has won additional contracts. A US technology company has signed a three-year agreement worth $400,000 and a university in Ireland a two-year deal worth $450,000. The share price improved 8.47% to 32p. Last December’s placing price was 29.66p.

Share buying by finance director Steve Winters has sparked a recovery in the share price of digital transformation services provider TPXimpact (LON: TPX). He has acquired 220,000 shares at 21.34p each. The share price rose 7% to 23p, although it has still halved this week.

Transport and logistics company Xpediator (LON: XPD) says 2022 revenues were nearly £400m, up from £297m. This means that profit will be much better than the £9m previously expected. Net debt has more than halved over six months to £3.6m. Freight forwarding operations in Lithuania, Bulgaria and Romania performed particularly well. The loss making Beckton warehouse will be closed in February. Bid discissions continue concerning the indicative offer of 42p a share. The share price moved up 5.92% to 40.25p.

Floorcoverings supplier James Halstead (LON: JHD) says interim revenues grew by 8-9% in the first half, which was held back by shipping problems. International freight availability is improving. Supply concerns have eased, and stocks have been reduced. WH Ireland is maintaining its 2022-23 pre-tax profit forecast at £50.1m, down from £52.1m because of higher costs. The share price was 5.98% higher at 195p.

The Orcadian Energy (LON: ORCA) share price has declined 9.09% to 10p. That is the price at which it raised £500,000 to fund the development of the Pilot licence area in the North Sea.

Yesterday afternoon, medical imaging technology developer Polarean Imaging (LON: POLX) has gained New Chemical Entity designation from the US FDA for its drug product XENOVIEW. There is a designated five-year market exclusivity period. XENOVIEW is a hyperpolarised contrast agent prepared from the Xenon Xe 129 gas blend that is used in magnetic resonance imaging. It can be used for evaluation of lung ventilation for patients aged 12 and older. It does not expose the patients to ionising radiation. The share price had time to rise 13.8% to 46.1p yesterday, but it has fallen back 4.56% to 44p.  

88 Energy (LON: 88E) is raising up to £8.1m (A$15.1m) at 0.55p a share, which was a one-fifth discount to the previous closing price. The oil and gas company had A$14.1m in cash at the end of December. The cash will fund the Hickory-1 well at project Phoenix (formerly Icewine East) in Alaska, pay for new project Leonis acreage and provide working capital. There should be enough cash for at least 12 months. Management is also seeking additional projects. The share price fell 5.3% to 0.625p.

Growth is accelerating at PCI -PAL (LON: PCIP) and revenues were one-third higher in the six months to December 2022, helped by currency movements. First quarter growth was 29%. Total annualised contract revenues are £14.7m. Net cash fell to £1.9m, but this should be enough to reach profitability. The share price declined by 5.26% to 54p.

Ex-dividends

Greencoat Renewables (LON: GRP) is paying a dividend of 1.54 cents a share and the share price was down 1.25 cents to 111.75 cents.

Ramsdens Holdings (LON: RFX) is paying a final dividend of 6.3p a share and the share price fell 5.5p to 228.5p.

Totally (LON: TLY) is paying an interim dividend of 0.5p a share and the share price slipped 0.35p to 24.25p.

Watkin Jones (LON: WJG) is paying a final dividend of 4.5p a share and the share price is 3.5p lower at 109.9p.

Superdry – Julian Dunkerton has no ‘current’ plans to take company private

Well now we have been told.

Superdry (LON:SDRY) Founder and Chief Executive Julian Dunkerton has answered press rumours about the possibility that he will look to take his iconic brand private.

The group, which had problems last year with pressures on its refinancing of a £70m facility, coupled with operating losses, recently declared that it enjoyed good Christmas retail sales, but a lower take on its wholesaling side.

City press headlines suggested that Dunkerton, with others, was considering taking the group private.

However, he has now confirmed that “there were no plans to do this at the moment” but he reserves the right to make or participate in an offer for Superdry within the next six months.

But he may do so if another party made an offer or he had agreement with the Superdry Board.

Analyst Opinion – long-term value

Analyst Wayne Brown at Liberum Capital recently stated that the group’s shares are cheap and offer significant long-term value. 

He sees the group’s profits recovering from a current year (to end May) loss of some £6m, bouncing up to a profit of £9m on increased sales of £645m. 

For 2025 his estimates are for £690m sales and £23.5m profits, worth 21.8p per share in earnings.

He has maintained his Buy rating on the shares, with a 500p Target Price.

Conclusion – options kept open

With its shares trading at around 118p, the group is currently capitalised at about £97m.

That sounds like he is definitely keeping his options open!

Shell profit hits $40bn record in 2022

Shell recorded a $40bn profit in 2022 as higher oil and gas prices caused by Russian aggression in Ukraine drove profits to the highest level for 115 years.

Adjusted earnings for 2022 rose to $39.9bn from $19.2bn in 2021 as earnings across their integrated gas, upstream, and chemical and products business units soared.

Fourth quarter results showed the impact of higher oil and gas prices was heavily weighted to the summer months and earnings from their upstream production activities fell sharply in the last quarter of the year. Adjusted earnings for the fourth quarter fell to $3bn from $5.9bn in the third quarter as energy prices fell.

Integrated gas was the standout performer in the fourth quarter with adjusted earnings rising 157% to $5.9bn.

Shell shares were 1.9% higher at 1.9% at the time of writing.

“Despite lower oil and gas prices over the final quarter of 2022, Shell’s adjusted earnings rose to $9.8m from $9.4m in the previous quarter, with higher LNG trading and optimisation results,” said Derren Nathan, head of equity research, Hargreaves Lansdown.

“Total earnings for 2022 of $39.9m came in ahead of analyst expectations. This gave Shell the confidence to increase its final dividend by 15% and earmark $4bn for share buyback in the first quarter of 2023.”

Nathan also touched on how Shell is increasingly banging their renewables drum. Shell’s renewables unit recorded $1.7bn adjusted earnings in 2022 and marked a swing to profits from a $243m loss in 2021. Renewables earnings is still relatively insignificant compared to Shell’s overall profit, but the profit certainly signals Shell’s future intentions.

“Shell was keen to point out its expansion in renewables, such as the recent acquisition of biogas producer Nature Energy and its JV with Ecowende which has won a bid to develop a 760 MW offshore wind farm in the Netherlands. This comes against the backdrop of a complaint to the SEC by activist Group Global Witness, that Shell is overplaying its investments in renewables,” Nathan said.

BT revenue and profit falls in inflation-related slowdown

BT shares started Thursday trade on the back foot following a disappointing trading update for the nine months to end 31st December.

The telecoms company saw their revenue fall as a result of inflationary pressures, lower equipment sales and the removal of BT Sport revenue.

Revenue declined 1% while profit before tax for the period sank 15%. Profit before tax was heavily impacted by deprecation costs which offset a jump in EBITDA.

The lower profit was recorded despite efforts to lower costs across the business. The group plan to save £3bn in annualised costs by the end of 2025.

“Cost cuts remain the aim of the game as BT battles with higher costs from a host of angles. To be fair, management look to be doing a decent job and synergies from the newly created BT Business should help make the £3bn cost saving target a reality – but there’s no avoiding the fact cash flow is under pressure,” said Matt Britzman, equity analyst at Hargreaves Lansdown.

Analysts also pointed out the challenging nature of BT’s sector. There is increasing competition and their top line growth is kept in check by customer’s ability to switch providers and pressure from regulators. This creates a model that is heavily reliant on reducing costs to boost profits.

“Telecoms is a mighty challenging sector. There’s little to differentiate providers and regulators and consumers are always demanding more for less. So while BT is pushing through price increases, it must be careful not to push too hard,” said Charlie Huggins, Head of Equities at Wealth Club.

“Then there are the huge cash demands – BT will spend around £5 billion this year alone to maintain and upgrade its infrastructure, and it will have to keep the spending taps open to remain competitive. If inflation remains elevated, these costs are only likely to increase.”

BT shares were trading down 0.7% at 122p at the time of writing, after recovering from lower levels earlier in the session.

Why companies left AIM in December

There were twelve AIM cancelations during December 2022. Savannah Energy (LON: SAVE) was readmitted on 13 December after completing a deal with ExxonMobil. Kistos Holdings (LON: KIST) changed its holding company and was readmitted.
Three companies were taken over, three companies decided to leave, one what bust, one failed to return from suspension, one moved to the Main Market and the other decided to concentrate on its Nasdaq listing.
1 December 2022
Life Science REIT (LON: LABS)
Life Science REIT barely had a year on AIM, having joined on 19 November 2011 when it raised £350m at 100p a shar...

Additional FDA approval for Polarean Imaging diagnostic product

1

Medical imaging technology developer Polarean Imaging (LON: POLX) has gained New Chemical Entity designation from the US FDA for its drug product XENOVIEW. There is a designated five-year market exclusivity period. The share price rose 13.8% to 46.1p.  

XENOVIEW is a hyperpolarised contrast agent prepared from the Xenon Xe 129 gas blend that is used in magnetic resonance imaging. It can be used for evaluation of lung ventilation for patients aged 12 and older. It does not expose the patients to ionising radiation. This diagnostic technology could be relevant to more than 30 million Americans suffering from chronic lung disease.

A new clinical study is planned to expand the range of clinical applications for the technology. The trial is being designed.

Polarean Imaging is estimated to have generated revenues of £1.5m in 2022 and they are expected to jump to $9.8m this year. The XENOVIEW product could be eligible for reimbursement of $250/scan.  

Losses are set to continue to be significant and the cash pile will be reduced. Net debt could fall below $3m by the end of 2023. That suggests that a fundraising will be required in the next 12 months. If the latest news and other positive announcements push up the share price, then a fundraising will be less dilutive.

FTSE 100 edges higher as US rate decision eyed

The FTSE 100 rose on Wednesday after a a strong session in the US overnight driven by central bank expectations.

The FTSE 100 had edged up 0.2% to 7,786 at the time of writing.

Nervousness earlier in the week has been replaced by mild optimism the Federal Reserve and Bank of England would soon start to slow the pace of their rates hikes, and could even cut rates towards the end of the year.

The prospect of easier monetary policy buoyed US stocks overnight where the S&P 500 closed up over 1%.

“The FTSE 100 moved higher on Wednesday morning, with today’s trading session in London sandwiched by strong gains on Wall Street overnight and the US Federal Reserve’s decision on interest rates later,” said AJ Bell investment director Russ Mould.

“A lot is riding on the Fed dialling back the pace of rate hikes to 25 basis points and there will also be plenty of attention on the surrounding messaging from chair Jerome Powell and his colleagues. Helping the market’s mood on Tuesday was data that revealed slowing US wage growth, another signal that inflationary pressures have peaked.”

GSK

GSK, formerly known as GlaxoSmithKline, dipped slightly on Wednesday after the pharma giant reported strong sales growth for 2022. GSK shares had been bid up over the last week and the numbers proved to be lacking the punch to keep the rally going through the trend line in a downtrend started in December.

“GSK, or Glaxo as market greybeards still know it as, reported underlying sales growth of 13% for the year just ended. Currency moves pushed the reported numbers up even higher,” said Steve Clayton, head of equity funds at Hargreaves Lansdown.

“Growth was driven by specialty medicines, up 29% and HIV treatments, 12% higher. The rest of the portfolio saw strong gains also from oncology and immuno-inflammation treatments.  Blockbuster shingles vaccine, Shingrix was the star of the show, delivering £3bn of sales, up 72%. The group currently has a pipeline of 69 treatments, 19 of which are in late-stage trials. Underlying earnings jumped by 18% to 110.8p.”

Entain

Entain was among the best performers on Wednesday following a record fourth quarter helped by growth in their US business and the World Cup.

The company also completed a number of European acquisitions which promise top line growth in 2022.

AIM movers: Pathfinder Minerals option exercised and Orcadian Energy funding

0

Pathfinder Minerals (LON: PFP) has received notice of the exercising by Acumen Advisory of the option to acquire its subsidiary IM Minerals and the rights to a claim against the Mozambique government. A binding agreement is required by 23 February. This will inject £2m in cash into Pathfinder Minerals and there could be more from a successful legal claim. The £500,000 placing at 0.5p a share has been completed. The share price jumped 35.3% to 0.575p.

Made Tech Group (LON: MTEC) announced positive trading and the share price moved up by 18.7% to 31.75p. This in contrast to TPXimpact, which also provides digital services to the public and private sector. First half revenues are 76% higher at £20.6m, meaning that it is well on the way to forecast full year revenues of £43m. Three recent major contract wins totalled £27m over two to four years. Margins have been low, but contractors are being used less and this will improve the margin. There is still a long way to go to get back to the September 2021 flotation price of 122p.

Crimson Tide (LON: TIDE) has secured the first US subscription contract for its mpro5 smart mobile working as a service product. The contract is worth more than £250,000 over three years. The mpro5 will be used as the front end for IoT sensors in the California offices of a global networking supplier. This could then be rolled out to other offices. The share price increased by 16.3% to 32p.

PetroTal Corp (LON: PTAL) has increased its 2P reserves by 24% to 96.7 million barrels. On the onshore Peru Bretana oil field. This comes from increased oil in place and higher an increased recovery factor. The NPV10 is estimated as $1.5bn. The share price rose 13.3% to 47p.

Kodal Minerals (LON: KOD) has received the $7m deposit from its funding package for the Bougani lithium project in Mali. This is being provided by Hainan Mining. The full funding is subject to Chinese regulatory approvals. Suay Chin decided not to take up the pre-emption rights that would be triggered by the subscription agreement that is part of the funding package. Results from drilling are pending. The share price is 14% ahead at 0.4475p.

Cybersecurity services provider ECSC (LON: ECSC) has won three significant contract wins. The managed detection and response division will provide services over three years for a total value of more than £690,000. The share price rose 13% to 26p.

Orcadian Energy (LON: ORCA) raised £500,000 at 10p a share to fund the progress towards a field development plan for the Pilot licence area in the North Sea. A farm-out process is underway. Upside resource potential for Pilot is 131MMbbl. Pro forma cash is £723,000. The share price fell 29.2% to 10.625p.

Digital transformation services provider TPXimpact (LON: TPX) continues to decline after yesterday’s reduction in full year guidance. It has slumped a further 25.5% to 19p, having started the week at 46p.

Synergia Energy Ltd (LON: SYN) says production at the Cambay C-77H well in India is being inhibited by the 1,500 metre column of gas in the wellbore. Management is considering solutions to this problem. The company plans to farm-out 50% of Cambay. The share price declined by 17.1% to 0.085p.

Made Tech Group – big Government contract wins boost record order book

The news that in the last few weeks Made Tech Group (LON:MTEC) has been awarded a massive £27m of new contracts by the Government, emphasises its potential to create sizeable profits in the coming year.

The £40m capitalised group is a specialist provider of digital, data and technology services to the UK public sector, enabling central government, healthcare and local government organisations to digitally transform.

The new contract wins are with the DVLA for £14m, the Department for Levelling Up, Housing and Communities for £8m and finally with the Cabinet Office for £5m.

Interim results due in next few weeks

Ahead of announcing its interims on Thursday 23 February the group issued a Trading Update declaring a strong first-half performance for the six months to end November 2022.

Group revenue was up 76% at £20.6m (£11.7m) while adjusted EBITDA was £0.5m (£1.2m), due to delayed bid submissions and ongoing project work.

The group had a net cash position of £9m, while its contracted order backlog at the period end was 53% up at a record £47.8m (£31.3m).

Going forward the group’s Board has confidence in its growth prospects, having right-sized its headcount, having reduced contractor numbers by 10% and improved cost controls.

CEO Rory MacDonald stated that:

 “We are delighted to have delivered another period of strong growth. It is pleasing to note that our contract sizes continue to grow as we become more established in the market. 

These wins, together with the new Home Office contract announced in November 2022, demonstrate Made Tech’s ability to deliver digital technology successfully, and highlight the strength of our reputation in this growing market. 

As a result, the Group remains on track to meet market expectations for the full year and deliver value to shareholders over the long term.”

Analyst Opinion – the most important indicators are flashing green

Analysts at Singer Capital Markets rate the shares as a Buy, looking for 76p a share.

Their estimates for the current year to end May are for £43.0m (£29.3m) revenues, with adjusted pre-tax profits rising to £3.4m (£2.3m), generating 3.4p (2.3p) per share of earnings.

For the next year they go for £50.0m sales, £4.1m profits and 2.6p earnings.

Conclusion – 40p for 2023 an easy objective

With its shares now trading around the 27p price level they are offering attractive upside, with 40p being an easy 2023 objective.